Last reviewed · How we verify
Lumify®
Lumify is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the eye to reduce redness.
Lumify is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the eye to reduce redness. Used for Reduction of conjunctival redness due to minor eye irritation.
At a glance
| Generic name | Lumify® |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Alpha-1 adrenergic receptor agonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine tartrate, the active ingredient in Lumify, selectively binds to alpha-1 adrenergic receptors on the conjunctival and episcleral blood vessels of the eye. This causes vasoconstriction, reducing blood flow to the conjunctiva and thereby decreasing the appearance of redness. The effect is rapid and temporary, typically lasting 8 hours.
Approved indications
- Reduction of conjunctival redness due to minor eye irritation
Common side effects
- Conjunctival blanching
- Eye irritation
- Mydriasis
Key clinical trials
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness (PHASE3)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis (PHASE3)
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive (PHASE4)
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PHASE3)
- Reliability of Minimally Trained Operator's Velocity-Time Integral Measurement Guided by Artificial Intelligence VTI (NA)
- "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness" (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lumify® CI brief — competitive landscape report
- Lumify® updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI